Description
MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model.WARNING This product is not for human or veterinary use.
References
[1] HAROLD E BAYS. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.[J]. The Journal of clinical endocrinology and metabolism, 2011: 2889-2897. DOI:
10.1210/jc.2011-1061[2] FAHRETTIN HACZEYNI. The selective peroxisome proliferator–activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice[J]. Hepatology Communications, 2017, 1 7: 663-674. DOI:
10.1002/hep4.1072
